E16.3
Increased secretion of glucagon
Clinical Classification Guidelines
Inclusion Terms
- Hyperplasia of pancreatic endocrine cells with glucagon excess
Medical Intelligence & Overview
Increased secretion of glucagon, classified under ICD-10 code E16.3, refers to a condition characterized by the excessive production of glucagon, a hormone produced by the pancreas. Glucagon plays an essential role in regulating blood sugar levels, particularly by promoting the release of stored sugar from the liver. When the secretion of glucagon is increased, it signifies an abnormal activity in the pancreatic endocrine cells, often associated with hyperplasia, or an increase in the number of cells, of those endocrine cells. This condition is linked to the overproduction of glucagon and can influence blood sugar regulation, potentially affecting overall metabolic health.
Causes & Symptoms
Clinical Causes: Hyperplasia of pancreatic alpha cells, leading to increased glucagon production Development of glucagon-secreting tumors (glucagonomas) Certain genetic mutations affecting pancreatic endocrine cell growth Chronic pancreatic diseases that modify endocrine cell function Endocrine cell hyperplasia due to other underlying hormonal imbalances
Key Symptoms: Elevated blood sugar levels (hyperglycemia) Unintended weight loss despite normal or increased food intake Diabetes-like symptoms such as frequent urination and increased thirst Skin rash or redness in some cases Fatigue or weakness Potential development of skin ulcers or infections
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically begins with blood tests to measure levels of glucagon and blood sugar. Imaging studies like ultrasound, CT scans, or MRI may be utilized to identify any tumors or abnormal growths in the pancreas. A biopsy might be performed if a tumor is suspected, to examine the endocrine cells more closely. Endocrinologists may also perform additional hormonal assessments to rule out other causes of hormone imbalance.
Treatment Protocols: Management of increased glucagon secretion depends on the underlying cause. Treatment options may include surgical removal of tumors or hyperplastic tissue, medications to regulate hormonal levels, or therapies aimed at controlling blood sugar levels. In cases where tumors are present, ongoing monitoring is essential to prevent complications. Lifestyle modifications and regular medical follow-up can also support overall health and well-being.
Clinical Advice & FAQs
Billing Guidance
Is E16.3 a billable ICD-10 code?
Yes, E16.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E16.3?
Clinical documentation must specify the nature of Increased secretion of glucagon and any associated comorbidities for accurate reporting.
Cite this Clinical Reference